Table 6 Subset analysis – overall survival

From: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

  

MST (months)

Subgroup

Number of patients (%)

CE

SPE

PS 0–1

162 (74)

10.9

10.1

PS 2–3

58 (26)

8.3

8.1

<70 years and PS 3

18 (8)

7.1

6.9

⩾70 years and PS 0–2

202 (92)

10.8

10.0

  1. CE, carboplatin plus etoposide; MST, median survival time; PS, performance status; SPE, split doses of cisplatin plus etoposide.
Back to article page